Europe – Page 20 – pharmaceutical daily

April 12, 2022 Off

Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease

By Author

Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, has entered into an agreement with Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.

April 12, 2022 Off

Marinomed Biotech AG signs new agreement for Carragelose with Hanmi Pharmaceutical in South Korea

By Author

Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, has announced today that the Carragelose-based nasal spray has been out-licensed for the South Korean market.

April 11, 2022 Off

Recipharm completes US biologics acquisitions

By Author

Recipharm, a global contract development and manufacturing organisation (CDMO), has announces the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics.

April 11, 2022 Off

Tjoapack doubles packaging capacity with completed Netherlands facility expansion

By Author

Global pharmaceutical contract packaging organisation (CPO), Tjoapack has completed its expansion plans following a €10m+ plus investment at its Etten-Leur facility in the Netherlands.

April 11, 2022 Off

Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates

By Author

Moderna, Inc. (NASDAQ:MRNA), has announced the first participants have been dosed in the Phase 1/2 study of the company’s seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030.

April 11, 2022 Off

Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

By Dino Mustafić

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), has announced positive results from preclinical studies evaluating an anti-HER3 antibody, conjugated with an Actinium-225 (Ac-225) radioisotope payload, for targeting HER3-positive non-small cell lung cancer (NSCLC) cells.

April 11, 2022 Off

Adrenomed Gets €7,4M to Develop Covid-19 Drug

By Author

Adrenomed AG, the vascular integrity company, has announced that its proprietary sepsis drug candidate Adrecizumab (HAM8101) received a funding commitment of € 7.4 million from the German Federal Ministry of Education and Research (BMBF) as part of the German funding initiatives for the clinical development of COVID-19 drugs and their manufacturing capabilities.

April 11, 2022 Off

SciRhom Starts CMC Development of its First Drug Candidate for Clinical Development

By Author

SciRhom GmbH has nominated the anti-iRhom2 antibody it will advance into clinical development. For this antibody, the company has closed an agreement with a top-tier biopharmaceutical manufacturer for the CMC development.

April 10, 2022 Off

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

By Dino Mustafić

Affimed N.V. (Nasdaq: AFMD) has provided a data update from the ongoing study of the company’s lead innate cell engager (ICE) AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells.

April 8, 2022 Off

Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement

By Author

Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab.